PharVision Advisers’s Thermo Fisher Scientific TMO Stock Holding History

PharVision Advisers’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-744	Closed	-$361K	–	1000
2025 Q3	$361K	Buy	+744	New	+$346K	0.2%	126
2025 Q2	–	Sell	-467	Closed	-$232K	–	428
2025 Q1	$232K	Buy	467 +46	+11%	+$24.9K	0.32%	152
2024 Q4	$219K	Buy	+421	New	+$231K	0.19%	264

Other funds holding TMO

JSC

J. Stern & Co London, United Kingdom $1.06B AUM 11.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

PharVision Advisers's TMO Position: Q4 2025 in Review

PharVision Advisers sold out of Thermo Fisher Scientific (TMO) in Q4 2025, closing a stake of 744 shares — an estimated $361K sold.

PharVision Advisers first reported a position in TMO in Q4 2024 and held it in 3 quarters. The position peaked at $361K in Q3 2025. 2,701 funds tracked by Wall St. Rank hold TMO as of Q4 2025.

PharVision Advisers reported no remaining Thermo Fisher Scientific position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 744 Thermo Fisher Scientific shares in Q4 2025, an estimated $361K.
PharVision Advisers first reported a position in Thermo Fisher Scientific in Q4 2024 and held it in 3 quarters.
PharVision Advisers's Thermo Fisher Scientific position peaked at $361K in Q3 2025.
2,701 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.